The Beijing Key Laboratory of Drug Target Research and Drug Screening was approved and established in 2011 based on the National Center for Pharmaceutical Screening of the Institute of Materia Medica, under the Chinese Academy of Medical Sciences & Peking Union Medical College. There are 21 research fellows in the Key Laboratory now. Among them, 18 have doctoral degree, 14 are professors, 7 are associated professors, 5 are Ph.D. supervisors, and 6 are master’s supervisors.
The development objectives are to establish novel strategies on drug target research and drug screening systems, and promote innovative drug development in China. The Center focuses on the demands of China’s social and pharmaceutical development, aims at the international leading researches of new drug development, and works with the bio-pharmaceutical industry in China to find treatments for diseases that seriously endanger human health. It centers on drug target discovery and validation, carrying out theoretical studies of drug discovery, establishing high-throughput drug screening models at both molecular and cellular levels, and using modern drug discovery techniques to carry out innovative drug screening.
The Key Laboratory mainly engages in the research of disease-related drug targets, establishment of drug screening models and the theoretical and technological studies of drug screening and discovery et al, and provides technical support for the development of Beijing’s pharmaceutical industry as well as new drug research and development in China.
The Key Laboratory has established various cooperating relationships with several pharmaceutical institutes around the world. The establishment of a high throughput drug screening technology platform provides technical services and sample screening services for international medicine research institutions and domestic institutions of higher learning, scientific research institutions and pharmaceutical companies. At the same time, it looks forward to cooperation and exchanges with more institutions to jointly promote the development of innovative drugs in China.
